Prevalence and risk factors for high-risk human papillomavirus infection in patients with immune-mediated inflammatory diseases: a prospective study
Authors' conclusion
The prevalence of HR-HPV infection in patients with IMID who are not up to date with CCS is 20%.
Study context
- Population
- Women aged 30–65 years with immune-mediated inflammatory diseases (IMID) not up to date with cervical cancer screening, French university hospital, March 2024 to May 2025; HPV screening with vaginal self-samplingmean age 48±10 years
- Participants
- 276 women
- Outcome
- HR-HPV infection prevalence
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
High-risk human papillomavirus (HR-HPV) detected
20%, n=55/276
Observational data: associations, not effects.
Further findings
Multiple HR-HPV infections (≥2 types) among HR-HPV-positive
- Multiple HR-HPV infections
- 35% (n=19/55)
Factors associated with HR-HPV infection (multivariable analysis)
- Age at first sexual intercourse, OR
- 0.85 (0.73 to 0.96) (95% CI)
- Number of lifetime sexual partners, OR
- 1.19 (1.05 to 1.38) (95% CI)
Duration of biological therapy and multiple HR-HPV infections
- Longer duration of biological therapy, OR
- 1.57 (0.99 to 2.85) (95% CI)
- Exploratory multivariable analyses
Original publication
Prevalence and risk factors for high-risk human papillomavirus infection in patients with immune-mediated inflammatory diseases: a prospective study. RMD Open. Published 15 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →